Question 1

What is combined oxidative phosphorylation defect type 23?

Accepted Answer

Combined oxidative phosphorylation defect type 23 is a condition that affects cellular energy production by impairing the mitochondrial oxidative phosphorylation process. It is caused by mutations in the GTPBP3 gene, which interfere with proper mitochondrial function. The condition presents early in life, with features such as muscle weakness and cardiomyopathy, and is considered very rare, affecting fewer than 1 in 1,000,000 individuals. Although symptoms can vary, the disorder primarily impacts the muscular, cardiac, and nervous systems.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 23?

Accepted Answer

Individuals with combined oxidative phosphorylation defect type 23 frequently exhibit increased circulating lactate levels and cytochrome C oxidase-negative muscle fibers, which are considered hallmark features of the disorder. Other common findings include hypertrophic cardiomyopathy and lactic acidosis, present in a significant proportion of cases. Affected infants may display hypotonia and a ‘floppy’ appearance, while some may experience abnormalities in the nervous system such as cognitive impairment and visual difficulties, though not all individuals develop every feature. That not all affected individuals experience all symptoms, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation defect type 23?

Accepted Answer

This condition is caused by mutations in the GTPBP3 gene, which plays a critical role in mitochondrial function and energy production. It is inherited in an autosomal recessive manner, meaning that an affected individual has inherited a mutated copy of the gene from each parent. Combined oxidative phosphorylation defect type 23 is more common when parents share a common ancestor, as this increases the likelihood that both carry the same rare variant. Genetic counseling is recommended for families to understand the inheritance pattern and implications for future pregnancies. Associated genes include GTPBP3.

Question 4

How is combined oxidative phosphorylation defect type 23 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 23 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 23?

Accepted Answer

combined oxidative phosphorylation defect type 23 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 23 diagnosed?

Accepted Answer

The diagnosis of combined oxidative phosphorylation defect type 23 is confirmed through molecular genetic testing that identifies pathogenic variants in the GTPBP3 gene. A comprehensive clinical evaluation is also performed, including assessment of the patient’s developmental history and biochemical markers such as elevated lactate levels. Because the clinical features can overlap with other conditions, genetic testing is essential to establish a definitive diagnosis.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 23?

Accepted Answer

Currently, management focuses on supportive care and symptom management, as there are no established foundational therapies or FDA-approved treatments for combined oxidative phosphorylation defect type 23. Treatment is highly individualized and typically involves a multidisciplinary team, which may include cardiologists, neurologists, and metabolic specialists, to address the multi-systemic nature of the disorder. Regular surveillance is an essential part of long-term care, ensuring that potential complications, such as cardiac issues or worsening muscle weakness, are identified and managed early. Patients should discuss treatment options with their healthcare team to determine which therapies and monitoring strategies are most appropriate for their situation.

Question 8

What are the common complications associated with combined oxidative phosphorylation defect type 23?

Accepted Answer

Common complications of combined oxidative phosphorylation defect type 23 include hypertrophic cardiomyopathy and lactic acidosis. These complications can affect the heart and muscles, leading to symptoms like muscle weakness and potential heart issues. Regular monitoring is important to identify and manage these complications early.

Question 9

How does combined oxidative phosphorylation defect type 23 affect daily life for patients?

Accepted Answer

Daily life for patients with combined oxidative phosphorylation defect type 23 can be challenging due to symptoms like muscle weakness and hypotonia. This may affect mobility and daily activities, requiring support from family and caregivers. A multidisciplinary team can help create a care plan that addresses individual needs and promotes the best quality of life.

Question 10

What is the prognosis for individuals with combined oxidative phosphorylation defect type 23?

Accepted Answer

The prognosis for individuals with combined oxidative phosphorylation defect type 23 varies widely. Many individuals can be managed effectively into childhood and beyond, but ongoing health challenges may arise. Regular care and monitoring are essential to address symptoms and complications, helping to optimize quality of life.

Question 11

What specialists should families consult for managing combined oxidative phosphorylation defect type 23?

Accepted Answer

Families managing combined oxidative phosphorylation defect type 23 should consult a team of specialists, including cardiologists, neurologists, and metabolic specialists. This multidisciplinary approach is important because the disorder affects multiple systems in the body. These specialists can help provide comprehensive care tailored to the individual’s needs.

Kisho

combined oxidative phosphorylation defect type 23

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

combined oxidative phosphorylation defect type 23

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 23?

What are the symptoms of combined oxidative phosphorylation defect type 23?

What causes combined oxidative phosphorylation defect type 23?

How is combined oxidative phosphorylation defect type 23 inherited?

How rare is combined oxidative phosphorylation defect type 23?

How is combined oxidative phosphorylation defect type 23 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 23?

What are the common complications associated with combined oxidative phosphorylation defect type 23?

How does combined oxidative phosphorylation defect type 23 affect daily life for patients?

What is the prognosis for individuals with combined oxidative phosphorylation defect type 23?

What specialists should families consult for managing combined oxidative phosphorylation defect type 23?

Explore clinical features